Nasdaq

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...
Hosted on MSN

GD2 CAR T treatment induces durable remissions in high-risk neuroblastoma

From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...
Nasdaq

Y-mAbs Presents GD2-SADA Pharmacokinetics Data At SNMMI And ACNM Annual Meeting

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid-Winter ...
Medscape

CAR T Anti-GD2 Shows Promise in Paediatric Neuroblastoma

Anti-disialoganglioside (GD2)-targeted third-generation chimeric antigen receptor T cells (GD2-CART01) have shown promising efficacy in children with high-risk metastatic, relapsed, and refractory ...
ascopubs.org

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival Eleven ...